Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
1570 results found
2025 ∙ Ali Sheikhi, R. Heidari, M. Doosti, P.
The role of religious leaders in the acceptance of COVID-19 vaccinations: a systematic review
All age groups COVID-19 Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Ojumu, A. Ibrahim, S. A. Seale, A. C. Fayehun, O. Gill, P.
Understanding factors influencing the implementation and uptake of less-established adult vaccination programmes: A meta-ethnography of COVID-19 vaccination in Nigeria
Africa Nigeria Adults Older adults Healthcare workers COVID-19 Coverage Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Satyam, S. M. El-Tanani, M. Bairy, L. K. Rehman, A. Srivastava, A. Kenneth, J. M. Prem, S. M.
Unraveling Cardiovascular Risks and Benefits of COVID-19 Vaccines: A Systematic Review
All age groups COVID-19 Efficacy/effectiveness Safety
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Jafari, Z. Kolb, B. E. Aiken, S. Wilson, S.
Updates on Auditory Outcomes of COVID-19 and Vaccine Side Effects: An Umbrella Review
All age groups Pregnant women COVID-19 Safety
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Gabor, M. Schlosserova, A. Korchynska, O. O.
Vaccination in pregnancy: a systematic review of current evidence
Pregnant women Influenza Pertussis COVID-19 Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Rehman, S. Sukaina, M. Aminpoor, H. Davis, S. Munir, A. B. I. Karimi, H.
Vaccine Induced Immune Thrombotic Thrombocytopenia After Sinopharm Vaccination: A Systematic Review of Case Reports
Adults Older adults COVID-19 Safety
Methodological quality (AMSTAR 2):
Low
2025 ∙ Hirsch, C. Zorger, A. M. Baumann, M. Park, Y. S. Bröckelmann, P. J. Mellinghoff, S. Monsef, I. Skoetz, N. Kreuzberger, N.
Vaccines for preventing infections in adults with solid tumours
Adults Older adults Pneumococcal disease Haemophilus influenzae type B Meningococcal disease Pertussis Hepatitis B Tetanus Poliomyelitis Diphtheria Influenza Herpes zoster COVID-19 Efficacy/effectiveness Safety
Methodological quality (AMSTAR 2):
High
2025 ∙ Hemrajani, P. Sharma, M. Gupta, S.
Vitiligo and coronavirus disease 2019 vaccination: A systematic review
All age groups COVID-19 Safety Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Conseil Supérieur de la Santé (CSS)
Belgian Vaccination Strategy against COVID-19: Season 2025-2026
Recommendation Europe Belgium COVID-19
Download:
2025 ∙ JCVI
JCVI statement on COVID-19 vaccination in autumn 2026 and spring 2027
Recommendation Europe United Kingdom COVID-19
Download:
Loading...